ISSCR News
Stem Cell Reports Welcomes New Members to Its Editorial Board
Expanding the depth and breadth of scientific expertise that defines Stem Cell Reports, the official journal of the International Society for Stem Cell Research, 13 distinguished researchers have joined the Editorial Board. Their appointment broadens representation across the diverse and international landscape of stem cell science and reinforces the Board’s commitment to championing the journal, raising its global visibility, and ensuring rigorous, high-quality peer review.
Kidney Organoid Unlocks Genetic Cause of Chronic Kidney Disease
Chronic kidney disease (CKD) affects more than 700 million people worldwide and is caused by genetic and environmental factors, as well as existing medical conditions. Known genetic risk factors for CKD include mutations in a gene called APOL1. These are rare in most populations, but two risk variants are present in as much as 13 percent of people with West African origin and another 38% possess one copy (carriers). The causes for APOL1-mediated kidney disease (AMKD) are currently not well understood, and treatments are lacking.
The ISSCR Partners with Nuffield Council on Bioethics to Compile Global Horizon Scan on Stem Cell Research
The International Society for Stem Cell Research (ISSCR) today announced a new partnership with the Nuffield Council on Bioethics (NCOB) to conduct an ambitious international horizon scan focused on the future of stem cell science and its ethical implications. The initiative will help signal and inform updates to the ISSCR Guidelines for Stem Cell Research and Clinical Translation and guide the Society’s broader public policy agenda.
The ISSCR and Novo Nordisk Foundation Collaborate to Host the Society’s 2028 Annual Meeting in Copenhagen
The International Society for Stem Cell Research (ISSCR) is proud to announce a collaboration with the Novo Nordisk Foundation to host the ISSCR Annual Meeting in Copenhagen, Denmark 27-30 June 2028.
The ISSCR Annual Meeting embodies the mission of both world-class organizations, supporting new frontiers in rigorous science to better human health. The conference is a revered global forum for stem cell science and regenerative medicine, uniting researchers, clinicians, industry leaders, and policy makers from more than 80 countries.
The ISSCR Responds to ICH’s Q1 Guideline on Stability Testing of Drug Substances and Drug Products
On 28 July, the ISSCR submitted a response to the International Council for Harmonisation’s (ICH) guideline on stability testing of drug substances and drug products. The ISSCR recommends adding specific examples to clarify appropriate applications of certain studies and incorporating considerations for diverse manufacturing models, particularly decentralized manufacturing, where products are administered immediately after production. The ISSCR also advises including guidance on pluripotent stem cell bank stability testing, referencing Tissue Engineered Products (TEP), and clarifying whether ATMP combined products are covered under the term “combination of a drug product with a medical device.”
To request the comments or learn more, contact Denise de Villa.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .